Mechanistic description
Convergence hypothesis: Both α-synuclein (SNCA) in Parkinson’s disease and tau (MAPT) in Alzheimer’s disease exploit the same synaptic vesicle cycle machinery for trans-synaptic propagation, making the vesicle trafficking pathway a shared therapeutic target.
PD-specific mechanism: α-synuclein binds to synaptic vesicles (SYP, SV2A, SYNPR) at the presynaptic terminal, inducing conformational conversion of endogenous α-synuclein into β-sheet-rich oligomers. These oligomers traffic in both directions across the synapse via activity-dependent exo/endocytosis, explaining the stereotypical pattern of Lewy body spreading (Braak stages I-VI).
AD-specific mechanism: Tau enters synapses via a distinct but overlapping mechanism: GSK3B-phosphorylated tau (pThr231, pSer396) binds to synaptic vesicle glycoprotein SYF2 and CPEB3, undergoing activity-dependent release in exosomes (SDPR, RSPH3). The tau seed competent strain propagates trans-synaptically and drives downstream amyloidogenic processing (APP, BACE1) in the receiving neuron.
Shared molecular targets (2+ per disease): • SNAP25/SNAP29 (PD: vesicle fusion; AD: tau release modulation) — both regulate exocytotic machinery • Dynamin-1 (DNM1) (PD: α-synuclein endocytosis; AD: tau endocytosis) — shared endocytic recycling • Synaptobrevin-2/VAMP2 (PD: SNARE complex; AD: activity-dependent release) — both require SNARE machinery • Caveolin-1 (CAV1) (PD: lipid raft entry; AD: tau entry via lipid rafts) — shared membrane microdomain entry
Falsifiable predictions:
-
SNAP25 knockdown in A53T SNCA;MAPT P301S double-transgenic mice will reduce both phospho-Ser129 α-synuclein AND phospho-Ser396 tau in the hippocampus by >50%.
-
Human post-mortem tissue from PD (Braak III-IV) and AD (Braak V-VI) both show increased DNM1 and decreased VAMP2 at the synapse compared to controls.
-
A dual-targeted peptide blocking both α-synuclein and tau interaction with VAMP2 will reduce propagation in humanized synuclein/tau mouse models.
Cross-references: Bridges h-1dc6387ca9 (Exosomal α-Synuclein Propagation in PD) and tau-spread hypotheses.
Mechanism / pathway
- SNCA,MAPT,SNAP25,DNM1,VAMP2,CAV1
- Synaptic vesicle cycle; Trans-synaptic propagation
- neurodegeneration
Evidence for (5)
Human iPSC 4R tauopathy model uncovers modifiers of tau propagation.
Amyloid-β predominant Alzheimer's disease neuropathologic change.
Transcriptional regulation by PHGDH drives amyloid pathology in Alzheimer's disease.
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
The associations between the MAPT polymorphisms and Alzheimer's disease risk: a meta-analysis.
Evidence against (1)
Evidence matrix
Supporting
- Human iPSC 4R tauopathy model uncovers modifiers of tau propagation. PMID:38582079 · 2024 · Cell
- Amyloid-β predominant Alzheimer's disease neuropathologic change. PMID:39417691 · 2025 · Brain
- Transcriptional regulation by PHGDH drives amyloid pathology in Alzheimer's disease. PMID:40273909 · 2025 · Cell
- Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial. PMID:37095250 · 2023 · Nat Med
- The associations between the MAPT polymorphisms and Alzheimer's disease risk: a meta-analysis. PMID:28415654 · 2017 · Oncotarget
Contradicting
No contradicting evidence recorded.
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). Synaptic Vesicle Cycle Hijacking: Shared Convergent Mechanism for α-Synuclein (…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-3f9740bfa5
@misc{scidex_hypothesis_h3f9740b,
title = {Synaptic Vesicle Cycle Hijacking: Shared Convergent Mechanism for α-Synuclein (…},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-3f9740bfa5},
note = {SciDEX artifact hypothesis:h-3f9740bfa5}
}